€36.92
0.70% yesterday
Xetra, Feb 04, 05:35 pm CET
ISIN
DE0005785604
Symbol
FRE
Sector

Fresenius Stock price

€36.92
+2.70 7.89% 1M
+5.97 19.29% 6M
+3.38 10.08% YTD
+11.40 44.67% 1Y
-0.07 0.19% 3Y
-9.83 21.02% 5Y
-12.72 25.62% 10Y
Xetra, Closing price Tue, Feb 04 2025
-0.26 0.70%
ISIN
DE0005785604
Symbol
FRE
Sector

Key metrics

Market capitalization €20.79b
Enterprise Value €33.19b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 14.75
EV/Sales (TTM) EV/Sales 1.49
P/S ratio (TTM) P/S ratio 0.94
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth -39.55%
Revenue (TTM) Revenue €22.21b
EBIT (operating result TTM) EBIT €1.50b
Free Cash Flow (TTM) Free Cash Flow €2.25b
Cash position €1.49b
EPS (TTM) EPS €-0.68
P/E forward 20.30
P/S forward 0.96
EV/Sales forward 1.54
Show more

Create a Free Account to create an Fresenius alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Fresenius Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Fresenius forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Fresenius forecast:

Buy
89%
Hold
11%

Financial data from Fresenius

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
22,208 22,208
40% 40%
100%
- Direct Costs 16,919 16,919
39% 39%
76%
5,289 5,289
41% 41%
24%
- Selling and Administrative Expenses 1,630 1,630
49% 49%
7%
- Research and Development Expense 668 668
21% 21%
3%
2,991 2,991
39% 39%
13%
- Depreciation and Amortization 1,491 1,491
42% 42%
7%
EBIT (Operating Income) EBIT 1,500 1,500
36% 36%
7%
Net Profit -383 -383
239% 239%
-2%

In millions EUR.

Don't miss a Thing! We will send you all news about Fresenius directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Stock News

AD HOC NEWS
2 days ago
Fresenius DE0005785604 wird anders als geplant das internationale Projektgeschäft seiner früheren Beteiligungsgesesellschaft Vamed doch nicht schrittweise einstellen.
AD HOC NEWS
3 months ago
Die DZ Bank hat den fairen Wert für die Aktien von Fresenius DE0005785604 von 42 auf 43 Euro angehoben und die Einstufung auf "Kaufen" belassen.
AD HOC NEWS
3 months ago
Die Bilanz für das dritte Quartal hat am Mittwoch den Aktien von Fresenius DE0005785604 viel Rückenwind gegeben.
More Fresenius News

Company Profile

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises dialysis products and healthcare services. The Fresenius Kabi segment specializes intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Michael Sen
Employees 193,865
Founded 1912
Website www.fresenius.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today